Could CAR-T therapy tame tough kidney disease?
NCT ID NCT07266181
First seen Jan 11, 2026 · Last updated May 17, 2026 · Updated 20 times
Summary
This early-stage trial tests a new treatment for people with a severe type of kidney disease called refractory membranous nephropathy. The treatment uses specially engineered immune cells (CAR-T cells) to target and destroy certain immune cells that may be causing the kidney damage. Only 5 participants will receive the therapy, and the main goal is to check for safety and side effects over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MEMBRANOUS NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Nephrology, Xijing Hospital
RECRUITINGXi'an, China, 710012, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.